# Kartos Therapeutics

Source: https://onco.cc/companies/kartos-therapeutics/  
OnCo record `kartos-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Kartos Therapeutics is a United States-based biotechnology company running 3 late-stage cancer trials of KRT-232 and Ruxolitinib in myeloproliferative neoplasms, endometrial cancer and diffuse large B-cell lymphoma.

## Summary

Kartos Therapeutics, based in Redwood City, the United States, is a biotechnology company. Kartos Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapeutics for patients with cancer. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing KRT-232 and Ruxolitinib in myeloproliferative neoplasms, endometrial cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and hodgkin lymphoma. The largest, NCT05797831 (Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer), plans to enrol 268 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Kartos Therapeutics, Inc.
- Tags: ctgov-sponsor
- HQ: Redwood City
- Type: biotech
- Website: https://www.kartosthera.com

## Sources

- Official website: https://www.kartosthera.com
- ClinicalTrials.gov: trials led by Kartos Therapeutics: https://clinicaltrials.gov/search?lead=Kartos%20Therapeutics%2C%20Inc.

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [KRT-232](https://onco.cc/drugs/krt-232/)
- trials: [KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera](https://onco.cc/trials/nct03669965/), [Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL](https://onco.cc/trials/nct04502394/), [Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer](https://onco.cc/trials/nct05797831/)

---
JSON: https://onco.cc/api/v1/entities/kartos-therapeutics.json